Adagene Inc. (FRA:978)
3.060
0.00 (0.00%)
Last updated: Jun 15, 2026, 8:06 AM CET
Adagene Revenue
In the year 2025, Adagene had annual revenue of $7.67M USD with 7,332.75% growth. Adagene had revenue of $7.67M in the half year ending December 31, 2025, with 840.35% growth.
Revenue
$7.67M
Revenue Growth
+7,332.75%
P/S Ratio
31.18
Revenue / Employee
$59.93K
Employees
128
Market Cap
203.73M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.67M | 7.57M | 7,332.75% |
| Dec 31, 2024 | 103.20K | -18.01M | -99.43% |
| Dec 31, 2023 | 18.11M | 8.82M | 94.90% |
| Dec 31, 2022 | 9.29M | -882.58K | -8.67% |
| Dec 31, 2021 | 10.18M | 9.47M | 1,351.72% |
| Dec 31, 2020 | 700.91K | 220.91K | 46.02% |
| Dec 31, 2019 | 480.00K | -1.03M | -68.24% |
| Dec 31, 2018 | 1.51M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biotest GmbH & Co. KGaA | 635.20M |
| Darwin AG | 54.30M |
| Paion AG | 14.81M |
| 2invest AG | 8.89M |
| MagForce AG | 1.08M |
| Biomark Diagnostics | 57.01K |
| co.don AG | 22.00K |
| bioXXmed AG | 20.49K |
Adagene News
- 27 days ago - Adagene Transcript: Stifel 2026 Targeted Oncology Virtual Forum - Transcripts
- 27 days ago - Adagene Slides: Investor presentation - Filings
- 4 weeks ago - Adagene to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Adagene presents data from two Phase 1b/2 studies of muzastotug at AACR - TheFly
- 2 months ago - Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types - GlobeNewsWire
- 2 months ago - Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board - GlobeNewsWire
- 2 months ago - Adagene price target raised to $10 from $9 at Guggenheim - TheFly
- 2 months ago - Adagene Slides: Investor presentation - Filings